Sai Parenterals Limited has proposed a significant reallocation of its initial public offering (IPO) proceeds, seeking shareholder approval to acquire controlling stakes in two private entities rather than pursuing organic capacity expansion and research development. The company intends to utilise ₹1,018.57 million from its unutilised IPO funds for these acquisitions, marking a pivot in its growth strategy amid regulatory headwinds in Hyderabad.

The Board of Directors, via a resolution dated August 11, 2026, recommended varying the objects of the prospectus issued on March 28, 2026. The IPO raised ₹409 crore through the issue of 1,04,28,288 equity shares at ₹392 per share. As of June 30, 2026, the company had utilised only a fraction of these funds, leaving substantial capital available for redeployment.

Proposed Acquisition Details

The company plans to acquire a 60% equity stake in Saicriti Pharma Private Limited and Prathyak Laboratories Private Limited. These acquisitions are designed to achieve the strategic objectives originally outlined in the IPO prospectus—capacity expansion and R&D capabilities—through inorganic growth.

Saicriti Pharma is constructing a state-of-the-art critical care injectable manufacturing facility at Gummadiadala, Hyderabad, designed to meet EU-GMP and USFDA standards. Prathyak Laboratories offers an established R&D platform at Genome Valley, providing immediate access to scientific personnel and an ongoing product pipeline.

Regulatory Drivers and Strategic Rationale

The decision to shift from organic expansion to M&A is primarily driven by the Government of Telangana’s Hyderabad Industrial Lands Transformation Policy (HILTP), introduced via G.O. Ms. No. 27 dated November 22, 2025. This policy mandates the phased relocation of manufacturing industries from the Core Urban Region of Hyderabad to clusters outside the Outer Ring Road (ORR).

Sai Parenterals noted that securing approvals for upgrading existing facilities within the identified urban areas has become challenging. Consequently, acquiring Saicriti Pharma, which is building outside the ORR, presents a more viable path to achieving international regulatory compliance and operational scale. Similarly, acquiring Prathyak Laboratories allows the company to bypass the execution risks and time delays associated with setting up a new R&D centre from scratch.

What the Numbers Show

The financial structure of this proposal reveals a high degree of capital efficiency regarding the R&D objective. The entire unutilised amount earmarked for the new R&D Centre (₹180.23 million) is being redirected entirely to acquire Prathyak Laboratories. In contrast, only a portion of the capacity expansion fund is being used for Saicriti Pharma (₹838.34 million out of ₹1,107.95 million raised), leaving ₹269.61 million of the original allocation still unassigned or potentially retained for other purposes related to Object 1, although the filing specifies the variation details for the acquisition amounts explicitly. This suggests the M&A route may be less capital-intensive than the original organic build-out plans, or that the valuations of the target companies are lower than the initial capex estimates.

Risks and Next Steps

The acquisitions are subject to definitive agreements, statutory approvals, and due diligence completion. Sai Parenterals highlighted integration risks, particularly the need to retain key scientific personnel at Prathyak and manage the construction and validation timelines at Saicriti Pharma’s facility. Notably, operations at Sai Parenterals’ Unit I and Unit II are proposed to remain suspended until commercial operations commence at the Saicriti facility, underscoring the operational dependency on this transaction.

Shareholders will vote on this special resolution during the 25th Annual General Meeting scheduled for September 10, 2026. Remote e-voting will be open from September 7 to September 9, 2026.

Sai Parenterals Limited reported a standalone net profit of ₹8.9 crore for the quarter ended June 30, 2026, marking a 975% year-on-year increase from ₹0.8 crore in Q1FY26. This significant turnaround was driven by a 175% surge in revenue from operations to ₹52.8 crore, compared to ₹19.2 crore in the corresponding period of the previous fiscal year. On a consolidated basis, which includes the full quarter impact of its Australian subsidiary Noumed Pharmaceuticals, revenue reached ₹182.4 crore against ₹34.6 crore last year, while consolidated net profit stood at ₹7.9 crore.

The Board of Directors approved these unaudited financial results on August 11, 2026. Statutory Auditors R. Kabra & Co. LLP issued an unmodified limited review conclusion on the standalone and consolidated financial statements. The company’s equity shares were listed on the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on April 2, 2026; consequently, comparative data for Q1FY26 is presented as unaudited information to facilitate comparability. Management noted that the year-on-year comparison is not like-for-like as Noumed was consolidated with effect from November 12, 2025.

Beyond financial performance, the Board approved strategic shifts in capital allocation. The company will utilize ₹83.83 crore, originally earmarked for upgrading Unit I and Unit II manufacturing facilities, to acquire a 60% equity stake in Saicriti Pharma Private Limited. This acquisition involves a state-of-the-art critical care sterile injectable manufacturing facility at Gummadidala, Hyderabad, with a total estimated development cost of ₹215 crore. Additionally, ₹18.02 crore allocated for establishing a new Research & Development Centre will be redirected to acquire a 60% stake in Prathyak Laboratories Private Limited, an established pharmaceutical R&D platform. Both acquisitions are subject to shareholder approval.

Key Financial Metrics (Standalone)

Key Financial Metrics (Consolidated)

What the Numbers Show

The divergence between standalone and consolidated performance highlights the weight of international subsidiaries in the group’s overall profile. While standalone EBITDA margin expanded significantly to 29.8% from 20.9% in Q1FY26 due to operating leverage, consolidated EBITDA margin contracted slightly to 14.9% from 17.1% in the prior year period. This contraction was primarily driven by elevated air-freight costs in Australia arising from industry-wide shipping disruptions and the fact that the Noumed platform currently operates at distribution margins pending the commencement of in-house manufacturing at Adelaide. However, gross margins improved sequentially to 41.8% from 38.1% in Q4FY26, indicating that negotiated price revisions are beginning to offset raw material cost increases. The standalone entity contributed 31% of consolidated revenue but 61% of consolidated EBITDA, underscoring the higher profitability of domestic operations compared to the international distribution arm.

Strategic Acquisitions and Expansion

The Board’s decision to vary the use of IPO proceeds aims to accelerate capacity expansion and R&D capabilities. The acquisition of a 60% stake in Saicriti Pharma Private Limited allows the company to bypass the lengthy land allotment process required for greenfield projects within the Outer Ring Road of Hyderabad, where upgradations are no longer permitted under the Hyderabad Industrial Lands Transformation Policy. The new facility at Gummadidala will provide approximately 154.66 million units of injectable capacity, roughly 47% more than the original plan, with completion targeted for April 2027. Similarly, acquiring Prathyak Laboratories provides immediate access to a pipeline of 150 SKUs and a team of 28 research scientists, supporting the company’s strategy to build an IP-led business. Funding for the AUD 53 million Australian facility has been completed, with Phase 1 manufacturing expected from April 2027.

Management reaffirmed its full-year guidance of ₹750 crore in revenue for FY27 at an EBITDA margin of around 17%. The year is weighted towards the second half, with the first quarter representing approximately 24% of the annual target. As on June 30, 2026, debt stood at approximately ₹310 crore against March 2026 debt of ₹319 crore, with cash and cash equivalents of ₹184 crore. The gross debt-to-equity ratio remains comfortably placed at 0.6 times even at peak debt levels expected during the ongoing CAPEX and acquisition program.